Blair AB, Yin LD, Pu N, et al. - This research sought to define the patterns and treatment of disease recurrence in patients achieving a pathological complete response (pCR) following neoadjuvant chemoradiation for advanced pancreatic ductal adenocarcinoma (PDAC). Between 2009 and 2017, patients with advanced PDAC who were treated with neoadjuvant therapy and had a pCR were distinguished. Researchers ascertained overall survival from the initiation of neoadjuvant, disease-free survival from the date of surgery, and post-recurrence survival (PRS) from the date of recurrence. Cox-regression model was used to examine factors associated with recurrence. Thirty achieved a pCR following neoadjuvant treatment and pancreatectomy out of 331 patients with borderline resectable or locally advanced PDAC. In patients with advanced PDAC, a pCR following neoadjuvant therapy is correlated with remarkable survival, although recurrence occurs in about half of patients. The results showed that individuals with pCR and recurrence respond well to treatment and survival remains encouraging. Advanced molecular characterization and longitudinal liquid biopsy may offer additional assistance with understanding tumor biologic behavior after achieving a pCR.